Company news

Exicure, Inc. news in 2021

Exicure, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

December 13, 2021

Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus

December 9, 2021

Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

November 18, 2021

Exicure Files Form 12b-25

November 14, 2021

Exicure to Present at Upcoming Scientific Conferences

October 27, 2021

Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

October 3, 2021

Exicure to Present at the Benzinga Healthcare Small Cap Conference

September 22, 2021

Exicure to Participate in Upcoming Scientific Conferences

September 14, 2021

Exicure to Participate in Upcoming Investor Conferences

August 31, 2021

Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress

August 11, 2021

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)

August 4, 2021

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference

August 3, 2021

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

August 1, 2021

Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day

July 7, 2021

Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference

June 28, 2021

Exicure, Inc. Announces Participation in Upcoming Conferences

June 2, 2021

Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)

May 12, 2021

Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress

May 11, 2021

Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress

March 10, 2021

Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors

March 8, 2021

Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

March 2, 2021

Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference

February 22, 2021

Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference

February 8, 2021

Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference

February 1, 2021

Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration

January 10, 2021

Exicure Announces Appointment of James Sulat to Board of Directors

January 4, 2021

Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day

January 3, 2021

Decks in 2021